News

May 17, 2011: BioAegis Therapeutics Signs Exclusive Option for Human Protein in Clinical Development

Plasma Gelsolin Could Hold the Key to the Body’s Ability to Localize Inflammation BOSTON MASSACHUSSETTS and MORRISTOWN, NEW JERSEY–(May 17, 2011) BioAegis Therapeutics, Inc. announced today that it has entered into an Exclusive Option Agreement with Brigham and Women’s Hospital for technology based on research of Dr. Thomas Stossel, Director, Translational Medicine at Brigham and …

May 17, 2011: BioAegis Therapeutics Signs Exclusive Option for Human Protein in Clinical Development Read More »